We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
34. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
35. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
36. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
37. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
38. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
39. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
40. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
41. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
42. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
43. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
45. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
46. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
47. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
48. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
49. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
50. Cow’s milk allergy: the future
- Dr. Carina Venter
-
51. Cow's milk allergy: management
- Dr. Carina Venter
-
52. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
53. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
54. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
55. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
56. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
57. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
58. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
59. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
60. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
61. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
63. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
64. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
65. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
66. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
67. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
68. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
69. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
70. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
71. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
72. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
73. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
74. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
75. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
76. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
77. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
78. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
79. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
80. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
81. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
82. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
83. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
84. AI and big data in drug discovery
- Mr. Ed Addison
-
85. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
86. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
87. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
88. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
89. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
90. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
91. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
92. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
93. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
94. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
95. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
96. New drugs for asthma
- Prof. Peter Barnes
-
97. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
98. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Faculty disclosure
- Chronic obstructive pulmonary disease (COPD)
- Learning objectives: Clinical characteristics
- COPD: key points
- Asthma vs. COPD: clinical characteristics
- Asthma vs. COPD: clinical differences
- COPD is NOT Asthma!
- Asthma vs. COPD: site & cells of inflammation
- Airway obstruction in asthma & COPD
- Learning objectives: Pathophysiology
- COPD is a small airways disease
- Small vs. large airways
- Inflammatory disorder involving small airways
- Airflow limitation in the small airways
- COPD physiology : small airways disease
- Learning objectives: Assessing the lungs
- Assessing the lungs
- Clinical imaging
- Physiology – spirometry
- FEV1 is a strong predictor of mortality in COPD
- Small airway disease: characteristics
- Assessment of small airway dysfunction
- Lung volumes
- Spirometry
- Flow-volume loops
- Novel spirometric measure
- Forced oscillation technique
- Low frequencies detect small airways
- Small-airway dysfunction among COPD patients
- Small airways & health status CAT score
- Learning objectives: Disease classification
- COPD classification
- GOLD 2014: management of COPD
- GOLD 2017: refined ABCD assessment tool
- Learning objectives: Therapeutic management
- GOLD 2017: recommendations for COPD
- Pneumonia and ICS in COPD
- Biomarker of stratifying ICS-sensitive COPD?
- Eosinophil in COPD: just another biomarker?
- Uncertainties in blood eosinophils
- Triple therapy in COPD
- When to use ICS in COPD management
- Thanks
Topics Covered
- Clinical characteristics and pathophysiology of COPD
- Pathophysiology of COPD
- Assessing the lungs in COPD
- COPD disease classification
- Therapeutic management of COPD
Links
Series:
- Advances in Chronic Obstructive Pulmonary Disease (COPD)
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Usmani, O.S. (2017, December 31). Updates in chronic obstructive pulmonary disease (COPD) [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/FDFR6952.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Omar S. Usmani, Speaker’s bureau: Takeda, Chiesi ; Grant/Research Support (Principal Investigator): Chiesi, GSK, Astra Zeneca, Takeda.
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Omar Usmani.
I'm a Reader in Respiratory Medicine at
Imperial College London and a Consultant Physician at the Royal Brompton Hospital.
I'm going to be talking about updates in Chronic Obstructive Pulmonary Disease, COPD,
particularly those in the last two years that have had an influence on
our clinical practice and may also help us guide research in the future years.
0:23
And this is my faculty disclosure and I wanted to emphasize that I have
no shares in any of the company and I have
no relationship of any kind with the tobacco industry.
0:34
So, I will review the anatomy and the pathology,
and how that relates to the physiology and importantly,
how that determines our management and treatment and
pharmacological approach of patients with COPD in the clinic.
0:49
So, I will review five key areas: clinical characteristics,
the Pathophysiology of patients with COPD,
how we're assessing the lungs and novel methods of assessing
the lungs that have appeared over the last few years,
the new disease classifications we have seen particularly this year, and also,
how that reflects on our new approach to
the therapeutic management of patients with COPD.
1:14
So, this year, we have seen the Global Initiative of
Obstructive Lung Disease or GOLD update their document.
And there are five key points related to COPD.
The first that we are aware of is that COPD is
a preventable and treatable disease that is
characterized by persistent respiratory symptoms.
Importantly, is point two,
and that the symptoms of dyspnea, cough,
and sputum production may actually be under-reported,
and a key point for us to reflect on this is our ability
to assess patients with COPD and find these patients,
not just in secondary care, but also primary care and using
Spirometry in an effective manner to find these patients.
The third point we see is that certainly
tobacco smoking is an important risk factor for COPD,
but a lot of research over the last few years has shown that biomass fuel exposure
and air pollution certainly may contribute to the manifestation of patients with COPD.
We also need to realize that COPD can be punctuated by periods of
acute worsening of respiratory symptoms called
exacerbations and we will pick up on this a little bit later.